PAI
ARCT icon

Palo Alto Investors’s Arcturus Therapeutics ARCT Stock Holding History

Palo Alto Investors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-38,970
Closed -$276K – 38
2017
Q3 		$276K Hold
38,970
– – 0.01% 39
2017
Q2 		$306K Hold
38,970
– – 0.01% 37
2017
Q1 		$311K Hold
38,970
– – 0.01% 38
2016
Q4 		$573K Hold
38,970
– – 0.03% 35
2016
Q3 		$674K Hold
38,970
– – 0.04% 38
2016
Q2 		$1.23M Buy
38,970
+2,657
+7% +$83.7K 0.09% 36
2016
Q1 		$963K Hold
36,313
– – 0.07% 38
2015
Q4 		$1.6M Hold
36,313
– – 0.09% 36
2015
Q3 		$1.53M Buy
36,313
+13,943
+62% +$733K 0.07% 39
2015
Q2 		$1.02M Buy
22,370
+11,915
+114% +$546K 0.05% 41
2015
Q1 		$412K Buy
+10,455
New +$460K 0.02% 45

Other funds holding ARCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Palo Alto Investors's ARCT Position: Q4 2017 in Review

Palo Alto Investors sold out of Arcturus Therapeutics (ARCT) in Q4 2017, closing a stake of 38,970 shares — an estimated $276K sold.

Palo Alto Investors first reported a position in ARCT in Q1 2015 and held it in 11 quarters. The position peaked at $1.6M in Q4 2015. 19 funds tracked by Wall St. Rank hold ARCT as of Q4 2017.

  • Palo Alto Investors reported no remaining Arcturus Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Palo Alto Investors sold 38,970 Arcturus Therapeutics shares in Q4 2017, an estimated $276K.
  • Palo Alto Investors first reported a position in Arcturus Therapeutics in Q1 2015 and held it in 11 quarters.
  • Palo Alto Investors's Arcturus Therapeutics position peaked at $1.6M in Q4 2015.
  • 19 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2017.

Based on Palo Alto Investors's 13F filing for Q4 2017, filed 14 Feb 2018.